Sustain-release lipid-liquid crystal formulations of pexiganan against Helicobacter pylori infection: in vitro evaluation in C57BL/6 mice.
C57BL/6
Cure rate: liquid crystal
Helicobacter pylori
Infection
Journal
BMC pharmacology & toxicology
ISSN: 2050-6511
Titre abrégé: BMC Pharmacol Toxicol
Pays: England
ID NLM: 101590449
Informations de publication
Date de publication:
11 Jan 2024
11 Jan 2024
Historique:
received:
28
08
2023
accepted:
03
01
2024
medline:
12
1
2024
pubmed:
12
1
2024
entrez:
11
1
2024
Statut:
epublish
Résumé
The Gram-negative bacterium Helicobacter pylori, H. pylori, is associated with significant digestive disorders. However, the effectiveness of bacterial eradication is declining due to drug resistance. A potent anti-H. pylori activity is shown by the natural antimicrobial peptide pexiganan. The current study aimed to evaluate the effectiveness of pexiganan and its lipid-liquid crystals (LLCs) in inducing Helicobacter pylori in mice. In this experimental study, H. pylori infection was first induced in C57BL/6 mice. Secondly, the antibacterial efficacy of pexiganan and its LLCs formulations was investigated to eliminate H. pylori infection. The H. pylori infection could not be completely eradicated by pexiganan peptide alone. However, incorporating pexiganan within the LLC formulation resulted in an increased elimination of H. pylori. Under the H&E strain, the pexiganan-LLCs formulation revealed minimal mucosal alterations and a lower amount of inflammatory cell infiltration in the stomach compared to the placebo. Clarithromycin was more effective than pexiganan at all tested concentrations. Furthermore, the pexiganan-loaded LLCs exhibited superior efficacy in curing H. pylori infection in a mouse model compared to pexiganan alone. This formulation can enhance H. pylori clearance while mitigating the adverse effects, typically associated with conventional drugs, leading to a viable alternative to current treatment options.
Identifiants
pubmed: 38212864
doi: 10.1186/s40360-024-00731-z
pii: 10.1186/s40360-024-00731-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9Informations de copyright
© 2024. The Author(s).
Références
McColl KE. Helicobacter pylori infection. N Engl J Med. 2010;362(17):1597–604.
pubmed: 20427808
doi: 10.1056/NEJMcp1001110
Keikha M, Sahebkar A, Yamaoka Y, Karbalaei M. Helicobacter pylori cagA status and gastric mucosa-associated lymphoid tissue lymphoma: a systematic review and meta-analysis. J Health Popul Nutr. 2022;41(1):1–1.
doi: 10.1186/s41043-021-00280-9
Fan F, Wang Z, Li B, Zhang H. Effects of eradicating Helicobacter pylori on metachronous gastric cancer prevention: a systematic review and meta-analysis. J Eval Clin Pract. 2020;26(1):308–15.
pubmed: 31141285
doi: 10.1111/jep.13179
Keikha M, Askari P, Ghazvini K, Karbalaei M. Levofloxacin-based therapy as an efficient alternative for eradicating Helicobacter pylori infection in Iran: a systematic review and meta-analysis. J Global Antimicrob Resist. 2021.
Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA, et al. The global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43(4):514–33.
pubmed: 26694080
doi: 10.1111/apt.13497
Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–27.
pubmed: 29276051
doi: 10.1016/S1473-3099(17)30753-3
Seo MD, Won HS, Kim JH, Mishig-Ochir T, Lee BJ. Antimicrobial peptides for therapeutic applications: a review. Molecules. 2012;17(10):12276–86.
pubmed: 23079498
pmcid: 6268056
doi: 10.3390/molecules171012276
Ge Y, MacDonald DL, Holroyd KJ, Thornsberry C, Wexler H, Zasloff M, et al. In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob Agents Chemother. 1999;43(4):782–8.
pubmed: 10103181
pmcid: 89207
doi: 10.1128/AAC.43.4.782
Lamb HM, Wiseman LR. Pexiganan acetate. Drugs. 1998;56(6):1047–52.
pubmed: 9878992
doi: 10.2165/00003495-199856060-00011
Neshani A, Zare H, Akbari Eidgahi MR, Hooshyar Chichaklu A, Movaqar A, Ghazvini K, et al. Review of antimicrobial peptides with anti-helicobacter pylori activity. Helicobacter. 2019;24(1):e12555.
pubmed: 30440101
doi: 10.1111/hel.12555
Shah S, Qaqish R, Patel V, Amiji M. Evaluation of the factors influencing stomach-specific delivery of antibacterial agents for Helicobacter pylori infection. J Pharm Pharmacol. 1999;51(6):667–72.
pubmed: 10454042
doi: 10.1211/0022357991772952
Nagahara N, Akiyama Y, Nakao M, Tada M, Kitano M, Ogawa Y, et al. Mucoadhesive microspheres containing Amoxicillin for clearance of Helicobacter pylori. Antimicrob Agents Chemother. 1998;42(10):2492–4.
pubmed: 9756746
pmcid: 105867
doi: 10.1128/AAC.42.10.2492
Wimley WC, Hristova K. Antimicrobial peptides: successes, challenges and unanswered questions. J Membr Biol. 2011;239(1):27–34.
pubmed: 21225255
pmcid: 3166253
doi: 10.1007/s00232-011-9343-0
Rajabalaya R, Musa MN, Kifli N, David SR. Oral and transdermal drug delivery systems: role of lipid-based lyotropic liquid crystals. Drug Des Devel Ther. 2017;11:393.
pubmed: 28243062
pmcid: 5315216
doi: 10.2147/DDDT.S103505
Lee DR, Park JS, Bae IH, Lee Y, Kim BM. Liquid crystal nanoparticle formulation as an oral drug delivery system for liver-specific distribution. Int J Nanomed. 2016;11:853.
Stevenson CL, Bennett DB, Lechuga-Ballesteros D. Pharmaceutical liquid crystals: the relevance of partially ordered systems. J Pharm Sci. 2005;94(9):1861–80.
pubmed: 16052511
doi: 10.1002/jps.20435
Chen Y, Ma P, Gui S. Cubic and hexagonal liquid crystals as drug delivery systems. BioMed research international. 2014;2014.
Lim JL, Ki MH, Joo MK, An SW, Hwang KM, Park ES, et al. An injectable liquid crystal system for sustained delivery of entecavir. Int J Pharm. 2015;490(1–2):265–72.
pubmed: 26004002
doi: 10.1016/j.ijpharm.2015.05.049
Guo C, Wang J, Cao F, Lee RJ, Zhai G. Lyotropic liquid crystal systems in drug delivery. Drug Discovery Today. 2010;15(23–24):1032–40.
pubmed: 20934534
doi: 10.1016/j.drudis.2010.09.006
Neshani A, Tanhaeian A, Zare H, Eidgahi MR, Ghazvini K. Preparation and evaluation of a new biopesticide solution candidate for plant disease control using pexiganan gene and Pichia pastoris expression system. Gene Rep. 2019;17:100509.
doi: 10.1016/j.genrep.2019.100509
Kamali H, Karimi M, Abbaspour M, Nadim A, Hadizadeh F, Khodaverdi E, Eisvand F, et al. Comparison of lipid liquid crystal formulation and Vivitrol® for sustained release of Naltrexone: in vitro evaluation and pharmacokinetics in rats. Int J Pharm. 2022;611:121275.
pubmed: 34748809
doi: 10.1016/j.ijpharm.2021.121275
Akiyama Y, Nagahara N, Kashihara T, Hirai S, Toguchi H. In vitro and in vivo evaluation of mucoadhesive microspheres prepared for the gastrointestinal tract using polyglycerol esters of fatty acids and a poly (acrylic acid) derivative. Pharm Res. 1995;12(3):397–405.
pubmed: 7617528
doi: 10.1023/A:1016208703380
Nagarajan D, Roy N, Kulkarni O, Nanajkar N, Datey A, Ravichandran S, Thakur C, Aprameya IV, Sarma SP, Chakravortty D, Chandra N, et al. Ω76: a designed antimicrobial peptide to combat carbapenem-and tigecycline-resistant Acinetobacter baumannii. Sci Adv. 2019;5(7):1946.
doi: 10.1126/sciadv.aax1946
Askari P, Namaei MH, Ghazvini K, Hosseini M. In vitro and in vivo toxicity and antibacterial efficacy of melittin against clinical extensively drug-resistant bacteria. BMC Pharmacol Toxicol. 2021;22:1–2.
doi: 10.1186/s40360-021-00503-z
Kleanthous H, Myers GA, Georgakopoulos KM, Tibbitts TJ, Ingrassia JW, Gray HL, Ding R, Zhang ZZ, Lei W, Nichols R, Lee CK, et al. Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infect Immun. 1998;66(6):2879–86.
pubmed: 9596763
pmcid: 108285
doi: 10.1128/IAI.66.6.2879-2886.1998
Ferrero RL, Thiberge JM, Huerre M, Labigne A. Immune responses of specific-pathogen-free mice to chronic Helicobacter pylori (strain SS1) infection. Infect Immun. 1998;66(4):1349–55.
pubmed: 9529052
pmcid: 108059
doi: 10.1128/IAI.66.4.1349-1355.1998
Wang X, Zhang Y, Gui S, Huang J, Cao J, Li Z, Li Q, Chu X, et al. Characterization of lipid-based lyotropic liquid crystal and effects of guest molecules on its microstructure: a systematic review. AAPS PharmSciTech. 2018;19(5):2023–40.
pubmed: 29869308
doi: 10.1208/s12249-018-1069-1
Johnsson M, Lam Y, Barauskas J, Tiberg F. Aqueous phase behavior and dispersed nanoparticles of diglycerol monooleate/glycerol dioleate mixtures. Langmuir. 2005;21(11):5159–65.
pubmed: 15896065
doi: 10.1021/la050175s
Kasahun GG, Demoz GT, Desta DM. Primary resistance pattern of Helicobacter pylori to antibiotics in adult population: a systematic review. Infect drug Resist. 2020;13:1567.
pubmed: 32547126
pmcid: 7266407
doi: 10.2147/IDR.S250200
Tsukamoto T, Nakagawa M, Kiriyama Y, Toyoda T, Cao X. Prevention of gastric cancer: eradication of Helicobacter pylori and beyond. Int J Mol Sci. 2017;18(8):1699.
pubmed: 28771198
pmcid: 5578089
doi: 10.3390/ijms18081699
Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59(8):1143–53.
pubmed: 20525969
doi: 10.1136/gut.2009.192757
De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, et al. Worldwide H. Pylori antibiotic resistance: a systematic. J Gastrointestin Liver Dis. 2010;19(4):409–14.
pubmed: 21188333
Megraud F, Bruyndonckx R, Coenen S, Wittkop L, Huang T-D, Hoebeke M, et al. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut. 2021;70(10):1815–22.
pubmed: 33837118
doi: 10.1136/gutjnl-2021-324032
Schubert JP, Woodman RJ, Mangoni AA, Rayner CK, Warner MS, Roberts-Thomson IC et al. Geospatial analysis of Helicobacter pylori infection in South Australia: should location influence eradication therapy? J Gastroenterol Hepatol. 2022.
Malfertheiner P, Megraud F, O’morain C, Gisbert J, Kuipers E, Axon A, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence consensus report. Gut. 2017;66(1):6–30.
pubmed: 27707777
doi: 10.1136/gutjnl-2016-312288
Chen CH, Lu TK. Development and challenges of antimicrobial peptides for therapeutic applications. Antibiotics. 2020;9(1):24.
pubmed: 31941022
pmcid: 7168295
doi: 10.3390/antibiotics9010024
Lee DK, Brender JR, Sciacca MF, Krishnamoorthy J, Yu C, Ramamoorthy A, et al. Lipid composition-dependent membrane fragmentation and pore-forming mechanisms of membrane disruption by pexiganan (MSI-78). Biochemistry. 2013;52(19):3254–63.
pubmed: 23590672
doi: 10.1021/bi400087n
Gottler LM, Ramamoorthy A. Structure, membrane orientation, mechanism, and function of pexiganan—a highly potent antimicrobial peptide designed from magainin. Biochim et Biophys Acta (BBA)-Biomembranes. 2009;1788(8):1680–6.
doi: 10.1016/j.bbamem.2008.10.009
Iwahori A, Hirota Y, Sampe R, MIYANO S, TAKAHASHI N, SASATSU M, KONDO I, NUMAO N, et al. On the antibacterial activity of normal and reversed magainin 2 analogs against Helicobacter pylori. Biol Pharm Bull. 1997;20(7):805–8.
pubmed: 9255424
doi: 10.1248/bpb.20.805
Zhang XL, Jiang AM, Ma ZY, Li XB, Xiong YY, Dou JF, Wang JF, et al. The synthetic antimicrobial peptide pexiganan and its nanoparticles (PNPs) exhibit the anti-helicobacter pylori activity in vitro and in vivo. Molecules. 2015;20(3):3972–85.
pubmed: 25738539
pmcid: 6272436
doi: 10.3390/molecules20033972
Navon-Venezia S, Feder R, Gaidukov L, Carmeli Y, Mor A. Antibacterial properties of dermaseptin S4 derivatives with in vivo activity. Antimicrob Agents Chemother. 2002;46(3):689–94.
pubmed: 11850249
pmcid: 127478
doi: 10.1128/AAC.46.3.689-694.2002
Radzishevsky IS, Rotem S, Bourdetsky D, Navon-Venezia S, Carmeli Y, Mor A, et al. Improved antimicrobial peptides based on acyl-lysine oligomers. Nat Biotechnol. 2007;25(6):657–9.
pubmed: 17529972
doi: 10.1038/nbt1309
Eren T, Som A, Rennie JR, Nelson CF, Urgina Y, Nüsslein K, Coughlin EB, Tew GN, et al. Antibacterial and hemolytic activities of quaternary pyridinium functionalized polynorbornenes. Macromol Chem Phys. 2008;209(5):516–24.
doi: 10.1002/macp.200700418
Flamm RK, Rhomberg PR, Simpson KM, Farrell DJ, Sader HS, Jones RN, et al. In vitro spectrum of pexiganan activity when tested against pathogens from diabetic foot infections and with selected resistance mechanisms. Antimicrob Agents Chemother. 2015;59(3):1751–4.
pubmed: 25583717
pmcid: 4325814
doi: 10.1128/AAC.04773-14
Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance. World J Gastroenterol. 2014;20(29):9898.
pubmed: 25110420
pmcid: 4123371
doi: 10.3748/wjg.v20.i29.9898
Adebisi AO, Conway BR. Modification of drug delivery to improve antibiotic targeting to the stomach. Therapeutic Delivery. 2015;6(6):741–62.
pubmed: 26149788
doi: 10.4155/tde.15.35
Nikkam N, Asgari S, Saniee P. Antimicrobial activity of liposome-coated superparamagnetic iron oxide nanoparticles (SPIONs) on H. Pylori. Iran J Gastroenterol Hepatol (GOVARESH). 2021;26.
Fonseca DR, Moura A, Leiro V, Silva-Carvalho R, Estevinho BN, Seabra CL, Henriques PC, Lucena M, Teixeira C, Gomes P, Parreira P, et al. Grafting MSI-78A onto chitosan microspheres enhances its antimicrobial activity. Acta Biomater. 2022;137:186–98.
pubmed: 34634508
doi: 10.1016/j.actbio.2021.09.063
Wadsater M, Barauskas J, Nylander T, Tiberg F. Formation of highly structured cubic micellar lipid nanoparticles of soy phosphatidylcholine and glycerol dioleate and their degradation by triacylglycerol lipase. ACS Appl Mater Interfaces. 2014;6(10):7063–9.
pubmed: 24779728
doi: 10.1021/am501489e
Libster D, Aserin A, Garti N. Interactions of biomacromolecules with reverse hexagonal liquid crystals: drug delivery and crystallization applications. J Colloid Interface Sci. 2011;356(2):375–86.
pubmed: 21315366
doi: 10.1016/j.jcis.2011.01.047
Báez-Santos YM, Otte A, Mun EA, Soh BK, Song CG, Lee YN, Park K, et al. Formulation and characterization of a liquid crystalline hexagonal mesophase region of phosphatidylcholine, sorbitan monooleate, and tocopherol acetate for sustained delivery of leuprolide acetate. Int J Pharm. 2016;514(1):314–21.
pubmed: 27863678
doi: 10.1016/j.ijpharm.2016.06.138
Shiadeh SN, Khodaverdi E, Maleki MF, Eisvand F, Nazari A, Zarqi J, Hadizadeh F, Kamali H, et al. A sustain-release lipid-liquid crystal containing risperidone based on glycerol monooleate, glycerol dioleate, and glycerol trioleate: In-vitro evaluation and pharmacokinetics in rabbits. J Drug Deliv Sci Technol. 2022;70:103257.
doi: 10.1016/j.jddst.2022.103257
Ki MH, Lim JL, Ko JY, Park SH, Kim JE, Cho HJ, Park ES, Kim DD, et al. A new injectable liquid crystal system for one month delivery of leuprolide. J Controlled Release. 2014;185:62–70.
doi: 10.1016/j.jconrel.2014.04.034